SCHEDULE: RA Capital Discloses 9.7% Stake in Obsidian Therapeutics

RA Capital Management and its affiliates have reported beneficial ownership of 9.7% of Obsidian Therapeutics' common stock as of August 3, 2026.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have jointly filed a Schedule 13G.
• The filing indicates beneficial ownership of 5,957,103 shares of Obsidian Therapeutics, Inc. common stock.
• This represents approximately 9.7% of the class of securities outstanding as of August 3, 2026.
• RA Capital Management acts as the investment adviser for the funds holding these shares.
• The reporting persons have disclaimed beneficial ownership beyond their obligations under Section 13(d) of the Act.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it reports a significant ownership stake but does not indicate new strategic initiatives or performance metrics.

Positives

• Significant institutional ownership by RA Capital, a known healthcare-focused investment firm.
• The filing confirms a substantial stake (9.7%) in Obsidian Therapeutics, indicating confidence from a major investor.
• The reporting persons have sole voting and dispositive power over the reported shares, suggesting active management of their investment.

Negatives

• The filing is a Schedule 13G, which is an informational filing and does not inherently signal positive or negative company performance.
• No new strategic information or financial performance data is provided in this filing.

Risks

• The concentration of ownership by a single entity could influence corporate governance decisions.
• Changes in RA Capital's investment strategy could lead to significant buying or selling pressure on Obsidian Therapeutics' stock.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future performance.

Management Comments

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. expressly disclaim status as a 'group' for purposes of this Schedule 13G.
• RA Capital serves as investment adviser for each of the Fund, the Nexus Fund II and the Nexus Fund IV and may be deemed a beneficial owner.
• Each of the Fund, the Nexus Fund II and the Nexus Fund IV has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in its portfolio.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act.

Industry Context

StockSavvy.ai notes that significant ownership filings by investment firms like RA Capital are common in the biotechnology and pharmaceutical sectors, often indicating active engagement or strategic interest in early-stage or development-focused companies.

Stakeholder Impact

• Shareholders: The filing confirms a significant stake by a major investor, which could be perceived positively, but it does not provide performance data.
• Management: May face increased scrutiny or engagement from RA Capital regarding strategic decisions.
• Potential Investors: The filing highlights RA Capital's interest, which might attract further investor attention.

Next Steps

• The reporting persons will continue to monitor their investment in Obsidian Therapeutics.
• Amendments to this Schedule 13G will be filed as required by SEC regulations.

Key Dates

Keywords

Obsidian Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Healthcare Fund, Common Stock, Investment Adviser